AI-based clinical trial solutions market seen topping $8.5B by 2030

The global market for AI-based clinical trial solution providers is expanding as drugmakers and healthcare firms automate recruitment, monitoring and data analysis. The Business Research Company projects the market will more than double by 2030, with North America leading today and Asia-Pacific expected to grow fastest.

Why it matters: - AI is changing how clinical trials are designed, run and monitored. - The shift could lower costs, shorten study timelines and improve trial success rates for pharmaceutical and healthcare companies. - The market’s projected growth signals rising demand for tools that reduce manual work and improve data quality across the clinical trial process.

What happened: - The Business Research Company said the global AI-based clinical trial solution providers market rose from $3.03 billion in 2025 to a projected $3.72 billion in 2026. - The company forecast the market will reach $8.53 billion by 2030. - The report covered market trends, size and forecasts for 2026-2035. - North America held the largest market share in 2025. - Asia-Pacific is forecast to post the fastest growth in the coming years.

The details: - The 2026 forecast reflects a 22.9% compound annual growth rate. - The 2030 forecast implies a 23.0% CAGR. - Past growth was tied to manual patient recruitment, limited AI integration in clinical trials, traditional data management methods, high monitoring costs and fragmented oversight. - The report identified AI algorithm improvements, cloud-based trial platforms, funding for decentralized trial infrastructure, demand for real-time monitoring and pharma-AI partnerships as growth drivers. - The report highlighted these trends: AI-powered patient recruitment, AI-driven analytics, virtual and decentralized trials, real-world evidence, predictive modeling and automated regulatory compliance. - AI-based clinical trial solution providers develop technologies that apply artificial intelligence to study design, patient recruitment, data handling and regulatory compliance. - AI systems, including machine learning and deep learning, support automation, data-driven insights and more efficient workflows in trial operations. - A March 2024 U.S. Census Bureau report found AI adoption among U.S. companies rose from 3.7% in fall 2023 to 5.4% by February 2024. - The report said that increase shows accelerating AI adoption across industries, which is helping drive the market. - The report covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition of the market reports includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The Business Research Company offered a free sample report and the full market report through its website.

Between the lines: - The market outlook suggests AI is moving from an experimental tool to core infrastructure for clinical development. - The strongest growth themes point to broader industry pressure for faster trials, better patient matching and more automated compliance. - North America’s current lead and Asia-Pacific’s faster growth outlook suggest the market is still consolidating in mature healthcare systems while expanding in newer adoption centers.

What's next: - AI-based trial platforms are likely to expand as drugmakers increase use of decentralized study models and real-time analytics. - Further partnerships between pharmaceutical companies and AI vendors are expected to shape product development and adoption. - More automation in recruitment, monitoring and regulatory workflows should continue to push the market forward. - More information is available in the full report and a free sample.

The bottom line: - AI-based clinical trial solution providers are moving into a high-growth phase as pharma companies look for faster, cheaper and more data-driven ways to run studies.